S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

Precigen Stock Price, News & Analysis (NASDAQ:PGEN)

$1.18
+0.01 (+0.85%)
(As of 12/8/2023 ET)
Compare
Today's Range
$1.14
$1.21
50-Day Range
$0.89
$1.42
52-Week Range
$0.81
$2.29
Volume
832,960 shs
Average Volume
1.82 million shs
Market Capitalization
$293.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Precigen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
747.5% Upside
$10.00 Price Target
Short Interest
Bearish
12.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$35,250 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.34) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

568th out of 954 stocks

Pharmaceutical Preparations Industry

202nd out of 362 stocks


PGEN stock logo

About Precigen Stock (NASDAQ:PGEN)

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

PGEN Stock Price History

PGEN Stock News Headlines

Precigen Inc PGEN
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Precigen, Inc. (PGEN)
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
Precigen Recent Insider Activity
Fred Hassan Bought 185% More Shares In Precigen
Precigen (PGEN) Receives a Buy from Stifel Nicolaus
PGEN - Precigen, Inc.
Precigen (PGEN) Receives a Buy from H.C. Wainwright
JMP Securities Sticks to Their Buy Rating for Precigen (PGEN)
Precigen Q2 2023 Earnings Preview
See More Headlines
Receive PGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PGEN
Fax
N/A
Employees
209
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$14.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+747.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$28.32 million
Net Margins
-1,257.75%
Pretax Margin
-1,259.50%

Debt

Sales & Book Value

Annual Sales
$6.76 million
Book Value
$0.50 per share

Miscellaneous

Free Float
145,120,000
Market Cap
$293.72 million
Optionable
Optionable
Beta
1.80
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report














PGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Precigen stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGEN shares.
View PGEN analyst ratings
or view top-rated stocks.

What is Precigen's stock price target for 2024?

4 Wall Street analysts have issued 12 month price targets for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 747.5% from the stock's current price.
View analysts price targets for PGEN
or view top-rated stocks among Wall Street analysts.

How have PGEN shares performed in 2023?

Precigen's stock was trading at $1.52 at the start of the year. Since then, PGEN stock has decreased by 22.4% and is now trading at $1.18.
View the best growth stocks for 2023 here
.

When is Precigen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our PGEN earnings forecast
.

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) released its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The biotechnology company had revenue of $1.38 million for the quarter, compared to the consensus estimate of $2.68 million. Precigen had a negative net margin of 1,257.75% and a negative trailing twelve-month return on equity of 54.48%.

What ETF holds Precigen's stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 87,692 shares of PGEN stock, representing 0.90% of its portfolio.

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).

Who are Precigen's major shareholders?

Precigen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Iridian Asset Management LLC CT (0.81%), Northern Trust Corp (0.44%), Charles Schwab Investment Management Inc. (0.42%), Jacobs Levy Equity Management Inc. (0.28%), Bank of New York Mellon Corp (0.18%) and Fore Capital LLC (0.17%). Insiders that own company stock include David M Obstler, Dean J Mitchell, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rick L Sterling, Rutul R Shah, Steven Frank and Trading SA Ares.
View institutional ownership trends
.

How do I buy shares of Precigen?

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PGEN) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -